RECRUITING

Ph3 Multicenter, 3wk RDBPC Efficacy, Safety & PK Study of Evening Dosed MPH HCl ER Capsules (HLD200) in Children 4-5 Yr With ADHD

Conditions

Attention Deficit Hyperactivity Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.

Official Title

Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended-Release Capsules (HLD200) in Children Aged 4 to 5 Years With ADHD

Quick Facts

Study Start:2024-09-13

Study Completion:2026-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06431256

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:4 Years to 5 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD

Inclusion Criteria	Exclusion Criteria
1. Subject and the subject's parent(s)/legal guardian(s) must be available for the duration of the study. The subject's parent(s)/legal guardian(s) must be able to read, write, and/or understand at a level sufficient to provide signed and dated informed consent. In accordance with ICH GCP Guideline E6 and other applicable regulations, the Investigator, or a person designated by the Investigator, will obtain written informed consent from each subject's parent(s)/legal guardian(s) (and the subject's assent, if applicable) before any study-specific activity is performed. The Investigator will retain the original copy of each signed consent/assent document. 2. Subjects must be male or female children 4 to 5 years of age at the time of consent and assent (if applicable). 3. Subjects must have a diagnosis of ADHD as defined by the DSM-5 criteria with confirmation using the Mini - International Neuropsychiatric Interview for Children and Adolescents (MINI KID). 4. Subjects must meet the criteria for the therapeutic need for control of mild to moderate symptoms of ADHD at Screening (Visit 1) and/or Baseline (Visit 2) as determined by a medical evaluation and by an ADHD-RS-IV Preschool Version Parent score ≥ 93rd percentile cut-off normalized for sex in ≥ 1 of the following: Hyperactivity/Impulsivity subscale score (≥17 for boys; ≥14 for girls), Inattention subscale score (≥14 for boys; ≥12 for girls), or Total Score (≥32 for boys; ≥24 for girls); and a Clinical Global Impression - Severity (CGI-S) score ≥4. 5. Subjects must have a Peabody Picture Vocabulary Test 4 (PPVT-4) Standard Score ≥70 at Screening. 6. Subject has undergone an adequate course of nonpharmacologic treatment or has a severe enough condition in the opinion of the Investigator to consider enrollment without undergoing prior nonpharmacological treatment. 7. Subject's height and weight at Screening are between the 5th and 95th percentiles according to the Centers for Disease Control and Prevention growth charts by age and sex. 8. Subject must have a resting pulse less than 127 bpm, systolic and diastolic blood pressure below the 95th percentile for age and gender according to the 2017 American Academy of Pediatrics guidelines7 based on the average of 3 measurements 2 to 5 minutes apart at Visit 1 and Visit 2, (only a single measurement is required at Visit 2 unless an elevated excursion is noted which requires the averaged value of triplicate measurements). 9. Subject must be considered clinically appropriate for treatment with HLD200. 10. Subject must be in general good health based upon medical history, physical examination, clinical laboratory examinations, vital signs, and 12-lead electrocardiogram (ECG) assessment	1. History of, or current, medical condition, including gastrointestinal disorders (e.g., surgery, malabsorption syndrome, and other similar conditions), open-angle glaucoma, abnormally increased intraocular pressure (IOP), or laboratory result that, in the opinion of the Investigator, unfavorably alters the risk-benefit of study participation, may jeopardize subject safety, or may interfere with the satisfactory completion of the study and study related procedures. 2. Serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, severe hypertension, untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, known family history of sudden death, or other cardiac problems that may place the subject at increased vulnerability to the sympathomimetic effects of a stimulant drug. 3. History of seizure disorder (except febrile seizures prior to age 4 and with last occurrence at least 1 year prior to study participation), Tourette's disorder, or intellectual disability of minor severity or greater (DSM-5 criteria). 4. Subject has any diagnosis of psychosis, bipolar I or II disorder, major depressive disorder, anxiety disorder, eating disorder, conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, tic disorders, disruptive mood dysregulation disorder, intellectual disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances. Subjects with oppositional defiant disorder (ODD) are permitted to enroll in the study as long as ODD is not the primary focus of treatment, and, in the opinion of the Investigator, the ODD is mild to moderate, and eligible subjects with ODD are appropriate and cooperative during screening. Additionally, subject has any other conditions that, in the Investigator's opinion, may jeopardize subject safety or may interfere with the satisfactory completion of the study and study-related procedures. 5. Subject is currently considered at risk of suicide in the opinion of the Investigator, has previously made a suicide attempt, or has a history of, or is currently demonstrating active suicidal ideation or behavior. 6. History of severe allergic reaction or intolerance to MPH. 7. Alanine aminotransferase, aspartate aminotransferase, total bilirubin, or creatinine greater than 1.5 times the upper limit of normal. Elevated bilirubin due to Gilbert's syndrome is not exclusionary. 8. Use of prescription medications (except allowed medications) within 7 days of Baseline (Visit 2), except for ADHD stimulant medication (within 72 hours \[3 days\] of Baseline Visit 2), clonidine and guanfacine (5 days of Baseline Visit 2), atomoxetine (7 days of Baseline Visit 2), monoamine oxidase (MAO) inhibitors (14 days of Baseline Visit 2), and nonprescription/over-the-counter medications (except allowed medications) within the 3 days preceding Baseline (Visit 2). Medications not covered in allowed medications or prohibited medications must be cleared by the Medical Monitor prior to enrolling the subject. 9. Use of psychotropic medications including antidepressants, mood stabilizers, and antipsychotics within 14 days of Baseline. 10. Participation in a clinical trial with an investigational drug within the 30 days preceding study enrollment. 11. Initiation of non-pharmacological treatment within 30 days prior to Baseline (Visit 2). Subject may not initiate any new non-pharmacological treatment during the study. 12. Use of any other medications that might confound the results of the study or increase risk to the subject. 13. Subject is well-controlled on his/her current ADHD medication with acceptable tolerability. 14. In the opinion of the Investigator, the subject may have potential problems complying with the protocol or the procedures of the protocol, or for which the study could pose unnecessary safety risks. 15. Subject has a sibling or step-sibling that is concurrently participating in this study or who has previously participated in this study 16. Subject or caregiver is a participating Investigator, Sub-investigator, study coordinator, or employee of a participating Investigator, or is an immediate family member of the aforementioned. 17. Any factor, which in the opinion of the Investigator would jeopardize the evaluation or safety or be associated with poor adherence to the protocol

Inclusion Criteria

Exclusion Criteria

1. Subject and the subject's parent(s)/legal guardian(s) must be available for the duration of the study. The subject's parent(s)/legal guardian(s) must be able to read, write, and/or understand at a level sufficient to provide signed and dated informed consent. In accordance with ICH GCP Guideline E6 and other applicable regulations, the Investigator, or a person designated by the Investigator, will obtain written informed consent from each subject's parent(s)/legal guardian(s) (and the subject's assent, if applicable) before any study-specific activity is performed. The Investigator will retain the original copy of each signed consent/assent document.
2. Subjects must be male or female children 4 to 5 years of age at the time of consent and assent (if applicable).
3. Subjects must have a diagnosis of ADHD as defined by the DSM-5 criteria with confirmation using the Mini - International Neuropsychiatric Interview for Children and Adolescents (MINI KID).
4. Subjects must meet the criteria for the therapeutic need for control of mild to moderate symptoms of ADHD at Screening (Visit 1) and/or Baseline (Visit 2) as determined by a medical evaluation and by an ADHD-RS-IV Preschool Version Parent score ≥ 93rd percentile cut-off normalized for sex in ≥ 1 of the following: Hyperactivity/Impulsivity subscale score (≥17 for boys; ≥14 for girls), Inattention subscale score (≥14 for boys; ≥12 for girls), or Total Score (≥32 for boys; ≥24 for girls); and a Clinical Global Impression - Severity (CGI-S) score ≥4.
5. Subjects must have a Peabody Picture Vocabulary Test 4 (PPVT-4) Standard Score ≥70 at Screening.
6. Subject has undergone an adequate course of nonpharmacologic treatment or has a severe enough condition in the opinion of the Investigator to consider enrollment without undergoing prior nonpharmacological treatment.
7. Subject's height and weight at Screening are between the 5th and 95th percentiles according to the Centers for Disease Control and Prevention growth charts by age and sex.
8. Subject must have a resting pulse less than 127 bpm, systolic and diastolic blood pressure below the 95th percentile for age and gender according to the 2017 American Academy of Pediatrics guidelines7 based on the average of 3 measurements 2 to 5 minutes apart at Visit 1 and Visit 2, (only a single measurement is required at Visit 2 unless an elevated excursion is noted which requires the averaged value of triplicate measurements).
9. Subject must be considered clinically appropriate for treatment with HLD200.
10. Subject must be in general good health based upon medical history, physical examination, clinical laboratory examinations, vital signs, and 12-lead electrocardiogram (ECG) assessment

1. History of, or current, medical condition, including gastrointestinal disorders (e.g., surgery, malabsorption syndrome, and other similar conditions), open-angle glaucoma, abnormally increased intraocular pressure (IOP), or laboratory result that, in the opinion of the Investigator, unfavorably alters the risk-benefit of study participation, may jeopardize subject safety, or may interfere with the satisfactory completion of the study and study related procedures.
2. Serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, severe hypertension, untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, known family history of sudden death, or other cardiac problems that may place the subject at increased vulnerability to the sympathomimetic effects of a stimulant drug.
3. History of seizure disorder (except febrile seizures prior to age 4 and with last occurrence at least 1 year prior to study participation), Tourette's disorder, or intellectual disability of minor severity or greater (DSM-5 criteria).
4. Subject has any diagnosis of psychosis, bipolar I or II disorder, major depressive disorder, anxiety disorder, eating disorder, conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, tic disorders, disruptive mood dysregulation disorder, intellectual disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances. Subjects with oppositional defiant disorder (ODD) are permitted to enroll in the study as long as ODD is not the primary focus of treatment, and, in the opinion of the Investigator, the ODD is mild to moderate, and eligible subjects with ODD are appropriate and cooperative during screening. Additionally, subject has any other conditions that, in the Investigator's opinion, may jeopardize subject safety or may interfere with the satisfactory completion of the study and study-related procedures.
5. Subject is currently considered at risk of suicide in the opinion of the Investigator, has previously made a suicide attempt, or has a history of, or is currently demonstrating active suicidal ideation or behavior.
6. History of severe allergic reaction or intolerance to MPH.
7. Alanine aminotransferase, aspartate aminotransferase, total bilirubin, or creatinine greater than 1.5 times the upper limit of normal. Elevated bilirubin due to Gilbert's syndrome is not exclusionary.
8. Use of prescription medications (except allowed medications) within 7 days of Baseline (Visit 2), except for ADHD stimulant medication (within 72 hours \[3 days\] of Baseline Visit 2), clonidine and guanfacine (5 days of Baseline Visit 2), atomoxetine (7 days of Baseline Visit 2), monoamine oxidase (MAO) inhibitors (14 days of Baseline Visit 2), and nonprescription/over-the-counter medications (except allowed medications) within the 3 days preceding Baseline (Visit 2). Medications not covered in allowed medications or prohibited medications must be cleared by the Medical Monitor prior to enrolling the subject.
9. Use of psychotropic medications including antidepressants, mood stabilizers, and antipsychotics within 14 days of Baseline.
10. Participation in a clinical trial with an investigational drug within the 30 days preceding study enrollment.
11. Initiation of non-pharmacological treatment within 30 days prior to Baseline (Visit 2). Subject may not initiate any new non-pharmacological treatment during the study.
12. Use of any other medications that might confound the results of the study or increase risk to the subject.
13. Subject is well-controlled on his/her current ADHD medication with acceptable tolerability.
14. In the opinion of the Investigator, the subject may have potential problems complying with the protocol or the procedures of the protocol, or for which the study could pose unnecessary safety risks.
15. Subject has a sibling or step-sibling that is concurrently participating in this study or who has previously participated in this study
16. Subject or caregiver is a participating Investigator, Sub-investigator, study coordinator, or employee of a participating Investigator, or is an immediate family member of the aforementioned.
17. Any factor, which in the opinion of the Investigator would jeopardize the evaluation or safety or be associated with poor adherence to the protocol

Contacts and Locations

Study Contact

Collegium Pharmaceutical

CONTACT

781-713-3729

clinicaltrials@collegiumpharma.com

Study Locations (Sites)

HLD200-112 Study Site

Dothan, Alabama, 36303

United States

HLD200-112 Study Site

Anaheim, California, 92805

United States

HLD200-112 Study Site

Jacksonville, Florida, 32256

United States

HLD200-112 Study Site

Miami Springs, Florida, 33166

United States

HLD200-112 Study Site

Orlando, Florida, 32801

United States

HLD200-112 Study Site

Decatur, Georgia, 30030

United States

HLD200-112 Study Site

New Orleans, Louisiana, 70115

United States

HLD200-112 Study Site

Saint Charles, Missouri, 63304

United States

HLD200-112 Study Site

Lincoln, Nebraska, 68526

United States

HLD200-112 Study Site

Las Vegas, Nevada, 89128

United States

HLD200-112 Study Site

Summerville, South Carolina, 29486

United States

HLD200-112 Study Site

Memphis, Tennessee, 38119

United States

Collaborators and Investigators

Sponsor: Ironshore Pharmaceuticals and Development, Inc

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-13

Study Completion Date2026-05

Study Record Updates

Study Start Date2024-09-13

Study Completion Date2026-05

Terms related to this study

Additional Relevant MeSH Terms

Attention Deficit Hyperactivity Disorder